IMVT · Immunovant, Inc.

Current Thesis

Immunovant is now a one-asset company. Batoclimab missed the primary endpoint in both Phase 3 thyroid eye disease studies (announced 2026-04-02) and was discontinued across all indications, leaving IMVT-1402 (imeroprubart), an anti-FcRn antibody, carrying the entire equity. The narrative leg on offer is a platform re-rating: six programs, $797.8M of cash at 2026-06-30, and two readouts guided to the second half of calendar 2026 — difficult-to-treat rheumatoid arthritis (enrollment complete) and a cutaneous lupus proof-of-concept — ahead of registrational Graves' and myasthenia gravis topline in 2027.

What is measured: the 2026-09-04 close of $39.25, 12.7% under the $44.96 52-week high, RSI(14) at 23.5, and a three-month price change of +27.4%. What is inferred: that combination describes a fast unwind of a recent advance rather than a broken multi-month structure — the oscillator is at the bottom of its range while the quarter's gain is still intact. Nothing in the company's own calendar falls inside the next 30 days.

Bullish and bearish views on Immunovant, Inc.

The model's bull view on Immunovant, Inc. (IMVT), in brief: Cash and equivalents of $797.8M at 2026-06-30, which management describes as runway to the potential commercial launch of IMVT-1402 in Graves' disease (Q1 FY2027 release, 2026-08-06). The bear view: Batoclimab's double TED Phase 3 miss on 2026-04-02 removed the diversification and left the FcRn mechanism unproven in this company's hands at Phase 3. Both cases follow in full.

Bull Case

• Cash and equivalents of $797.8M at 2026-06-30, which management describes as runway to the potential commercial launch of IMVT-1402 in Graves' disease (Q1 FY2027 release, 2026-08-06). For a pre-revenue biotech, that removes the near-term financing question from the readout.
• R&D expense of $142.6M in the June 2026 quarter against $101.2M a year earlier, while G&A fell to $17.7M from $26.0M. Spend is being pushed into trials, not overhead.
• Six IMVT-1402 programs described as on track at the 2026-08-06 update: Graves' and myasthenia gravis registrational topline in 2027, CIDP and Sjögren's in 2028, D2T RA results and a CLE proof-of-concept in 2H CY2026.
• Phase 1 IgG reductions of 63–74% at the respective doses with a favourable safety profile, per the FY2026 Form 10-K — the pharmacodynamic case for 1402 over batoclimab.
• The Graves' registrational design uses 600 mg for up to 52 weeks with no step-down, and a 2025 company release reported 8 of 17 batoclimab responders reaching anti-thyroid-drug-free remission six months after treatment ended. Durable off-drug remission is the differentiation argument against chronic FcRn dosing.
• Sell-side sits above the tape: 16 analysts, consensus Buy, average target $48.88 with a $30–$66 range (S&P Global consensus as compiled by stockanalysis.com, retrieved 2026-09-05).

Bear Case

• Batoclimab's double TED Phase 3 miss on 2026-04-02 removed the diversification and left the FcRn mechanism unproven in this company's hands at Phase 3.
• The June quarter produced a $153.2M net loss, $(0.75) per share against a $(0.61) consensus. At that rate the $797.8M is a finite number, and "runway to launch" is management's characterisation of a future, not an audited fact.
• Both near-term readouts are guided to "2H 2026" — a window with no date attached, which can arrive in December or move into 2027 without the company breaking a stated commitment.
• The events that actually price the asset — Graves' and MG registrational topline — are 2027. That is roughly a year of carry with no de-risking print in between.
• The FY2026 10-K names dependence on the HanAll Biopharma license for core intellectual property, and states that Roivant Sciences owns a significant percentage of the shares and may exert significant control over matters subject to stockholder approval.
• The FcRn class is commercially occupied by argenx's efgartigimod franchise and Johnson & Johnson's nipocalimab; 1402 arrives into a bar that competitors keep raising.

Setup & Price Structure

The 2026-09-04 close of $39.25 sits 12.7% below the $44.96 52-week high with RSI(14) at 23.5, while the three-month change remains +27.4%. That is a shallow drawdown compressed into a short window, and the pullback has no company-dated event attached to it in the record — the annual meeting on 2026-09-02 was a routine director and auditor vote, not a data event.

On the upside, the structure does not confirm anything until the shares put a weekly close back above the $44.96 high; that is the level that turns a bounce into a new-high breakout. On the downside, $35 is the level where the giveback stops being a shakeout: a weekly close under it erases most of the three-month advance and returns price to the range it traded before the summer move.

Positioning observables, stated as observables rather than as a verdict: the consensus target of $48.88 sits well above the last close, so the sell-side is positioned ahead of the data rather than reacting to it; no insider transactions appear in the last-30-day filing record; there is no earnings date inside 30 days; and no theme cluster in this pipeline currently carries IMVT, so the bid is company-specific rather than a group move. On that evidence the narrative is maturing — the FcRn autoimmune story is well known, the single-asset structure has been public since 2026-04-02, and the flow behind it has thinned since the shares set the $44.96 high, with no dated company catalyst between now and the undated 2H CY2026 readouts.

Catalyst Calendar (next 30 days)

• 2026-09-05 to 2026-10-05: no confirmed company-dated catalyst. The 2026-09-02 annual meeting has elapsed. Any move in this window is driven by class read-across or biotech beta, not by Immunovant's own calendar.
• 2H CY2026 (undated): IMVT-1402 topline in difficult-to-treat rheumatoid arthritis; enrollment was reported complete in the FY2026 10-K.
• 2H CY2026 (undated): cutaneous lupus erythematosus proof-of-concept data.
• ~2026-11 (est.): fiscal Q2 FY2027 results, quarter ending 2026-09-30. Prior-year cadence puts the report in early-to-mid November; the company has not announced the date.
• 2027 (guided): Graves' disease and myasthenia gravis registrational topline.

What Would Change Our Mind

The read breaks first on structure: if the three-month advance is handed back, the "oversold inside an intact uptrend" description stops being true and the name reverts to a single-asset biotech waiting a year for its real print. The gradeable condition is a weekly close below $35.

Second, on the calendar: if the fiscal Q2 release around November re-guides D2T RA or CLE past 2026-12-31, the only near-term de-risking events disappear and the story shifts from maturing to a 2027 wait carrying a $153.2M quarterly burn.

Third, on the data: a 2H CY2026 release showing IMVT-1402 failing to separate from placebo on the primary endpoint in either study would put the mechanism question raised by batoclimab's TED failure back on the lead asset.

Fourth, on the balance sheet: an equity offering, ATM draw or convertible priced while the shares trade under the 52-week high would contradict the "runway to potential commercial launch" language from 2026-08-06 and reset the dilution assumption.

Correlation Notes

• Roivant Sciences (ROIV): the 10-K identifies RSL as holding a significant percentage of IMVT shares. IMVT data days move ROIV's stated net asset value, and the two names trade together on 1402 news.
• argenx (ARGX) and Johnson & Johnson (JNJ, nipocalimab): the FcRn class sets the efficacy and safety bar 1402 is measured against. Class data — particularly in Graves' or MG — reprices IMVT without any Immunovant release.
• XBI / clinical-stage biotech beta: with no revenue and 2027 catalysts, IMVT is a long-duration cash-flow asset and trades with rate expectations and biotech risk appetite between its own prints.
• No theme cluster: the pipeline's theme registry does not currently carry this name, so the thesis does not lean on a group move and cannot borrow support from one.